AIM ImmunoTech Inc.
Organization details
- Legal name
- AIM ImmunoTech Inc.
- Former names
- Hemispherx Biopharma Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Ocala
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AIM
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0000946644
- EIN
- 52-0845822
Board of directors
-
David I. Chemerow · DirectorSince 2025
-
Nancy Bryan · DirectorSince 2023
-
Stewart Appelrouth · DirectorSince 2023
-
Ted D. Kellner · DirectorSince 2024
-
Thomas K. Equels · Director · CEO & PresidentSince 2023
-
William M. Mitchell · DirectorSince 2024
Chief executives
Director election results
Annual meeting of December 17, 2024. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
49.2%
-
50.1%
-
51.4%
-
51.9%
-
54.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $44,498
- 11 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 11, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +35,000 | $0.15 | $5,215 |
| Nov 10, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +39,000 | $0.14 | $5,382 |
| Nov 9, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +31,298 | $0.16 | $5,070 |
| Nov 6, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +20,299 | $0.16 | $3,167 |
| Nov 6, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +12,751 | $0.16 | $2,015 |
| Oct 23, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +31,675 | $0.16 | $5,068 |
| Oct 22, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +31,250 | $0.16 | $5,094 |
| Sep 17, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +24,000 | $0.21 | $5,040 |
| Sep 16, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +11,000 | $0.21 | $2,310 |
| Sep 15, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +22,000 | $0.22 | $4,840 |
| Sep 14, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +5,900 | $0.22 | $1,298 |
| Mar 12, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Derivative conversion | +25,000 | — | — |
| Mar 12, 2026 | David I. Chemerow Director | Derivative conversion | +25,000 | — | — |
| Feb 5, 2026 | David I. Chemerow Director | Grant or award | +2,800 | $1.23 | $3,444 |
| Jun 13, 2025 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +107 | $7.70 | $824 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about AIM ImmunoTech Inc.
Who is the CEO of AIM ImmunoTech Inc.?
Thomas K. Equels is AIM ImmunoTech Inc.'s CEO & President.
How many directors are on AIM ImmunoTech Inc.'s board?
AIM ImmunoTech Inc.'s board has 6 directors: David I. Chemerow, Nancy Bryan, Stewart Appelrouth, Ted D. Kellner, Thomas K. Equels and William M. Mitchell.
Are AIM ImmunoTech Inc. insiders buying or selling shares?
Over the last 12 months, AIM ImmunoTech Inc. insiders bought $44,498 of shares in 11 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="aim-immunotech-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.